Our study, using data of prospective trials, demonstrated that the neutrophil-lymphocyte ratio (NLR) was associated with survival time in patients with KRAS wild-type metastatic colorectal cancer treated with firstline chemotherapy with cetuximab. The expression levels of the LYZ, TYMP, and CD68 genes differed significantly between the NLR-low and NLR-high groups. Genes encoding for activities on macrophages may affect the NLR. Background: Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-related genes affect the NLR remain unclear. Patients and Methods: In 77 patients with KRAS exon2 wild-type mCRC from prospective trials of first-line chemotherapy with cetuximab, expression levels of 354 immune-related genes were measured in tissue samples obtained from all patients by the HTG EdgeSeq Oncology Biomarker Panel. The association between the NLR and clinical outcomes was evaluated using the Spearman rank correlation coefficient. In addition, 2-sample t tests were performed to investigate which genes among the top 100 genes associated with survival had significantly different expression levels between the NLR-low and NLR-high groups among all measured genes. Results: NLR data were available for 71 patients. The NLR was associated with progression-free survival and overall survival (r ¼ À0.24; P ¼ .040 and r ¼ À0.29; P ¼ .010, respectively). When stratified by the median value of the NLR, the Kaplan-Meier curve of NLR-low versus NLR-high differed significantly for both progression-free survival (median, 11.8 vs. 9.1 months; P ¼ .036) and overall survival (median, 42.8 vs. 26.7 months; P ¼ .029). The 2-sample Clinical Colorectal Cancer December 2018 -e741 t test revealed that the expression levels of the LYZ, TYMP, and CD68 genes differed significantly between the NLRlow and NLR-high groups (t test P-value < .005; false discovery rate P-value < .15). Conclusion: NLR is significantly associated with survival in patients with mCRC treated with first-line chemotherapy with cetuximab. Genes encoding for activities on macrophages may affect the NLR.
Introduction
The neutrophil-to-lymphocyte ratio (NLR) is a marker of inflammation, and an elevated NLR reflects enhanced systemic inflammation and is associated with reduced tumor-specific immunity such as decreased tumor-infiltrating lymphocytes (TILs) in the tumor. 1 Neutrophils, monocytes, and platelets have been reported to promote tumor development via different mechanisms, whereas lymphocytes are essential for the elimination of cancer cells. 2 Distinct tumor-suppressive mechanisms are mainly controlled by CD4 and CD8 T lymphocytes, but regulatory T cell contributes to tumor-induced immunotolerance through suppression of the CD4 T lymphocyte. Various cytokines mediate the attraction of immune cells in the tumor microenvironment. A high NLR has been shown to correlate with a distinct cytokine profile including pro-inflammatory cytokines and angiogenic cytokines, which are related to key biological processes involved in carcinogenesis. 3 This may partly explain why an elevated NLR is associated with poor outcomes in cancer.
A systematic review and meta-analysis of 100 studies including 40,559 patients with various solid tumors indicated that NLR was associated with poor survival in all disease subgroups, sites, and stages. Meta-analyses and systemic reviews based on relevant studies showed that NLR has prognostic value in patients with colorectal cancer (CRC). An elevated pretreatment NLR predicted poorer survival in CRC. [4] [5] [6] The role of pretreatment inflammatory indices in predicting the outcomes of patients with CRC has been clearly evidenced in patients with radically resected tumors 7 and was more recently suggested in patients with metastatic disease. [8] [9] [10] [11] The NLR was a better independent predictor of outcomes than was the lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio, and prognostic nutritional index in patients with CRC. 12 A significant association of the NLR with clinical outcomes has been reported in several retrospective studies of patients with metastatic CRC (mCRC) treated with chemotherapy plus bevacizumab. 13, 14 A retrospective study of a large prospective trial, the TRIBE, validated the prognostic value of the NLR in patients with mCRC who received intensive chemotherapy with bevacizumab. 14 However, few clinical studies have investigated the association between the NLR and treatment with cetuximab-based chemotherapy. The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immunerelated molecular signals affect the NLR remain unclear. We therefore performed a biomarker study to evaluate association between the NLR and the clinical outcomes of cetuximab treatment for mCRC and to investigate which immune-related genes significantly affect the NLR.
Patients and Methods

Study Design and Patient Population
We conducted a retrospective study including patients with KRAS exon2 wild-type mCRC whose tissue samples were available for measurement of gene expression levels, from 2 prospective clinical trials evaluating the combination of cetuximab and oxaliplatin-based chemotherapy as first-line treatment, modified-FOLFOX6 (leucovorin, fluorouracil [FU] , and oxaliplatin þ cetuximab) (JACCRO CC-05 trial (Japan Clinical Cancer Research Organization): N ¼ 28/57, UMIN000004197), and SOX (S-1 and oxaliplatin þ cetuximab) (JACCRO CC-06 trial: N ¼ 49/67, UMIN000007022). The identical eligibility criteria of the 2 trials were as follows: adenocarcinoma of the colon or rectum with immunohistologic expression of EGFR; KRAS exon 2 wild-type tumor with unresectable metastases; at least 1 measurable lesion of 10 mm or a residual nonmeasurable lesion according to the Response Evaluation Criteria in Solid Tumors, version 1.1; adequate bone marrow function, hepatic function, and renal function; an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; and an age of 20 to 79 years. Patients with uncontrolled infection, massive ascites or pleural effusion, symptomatic brain metastases, or other malignancies within 5 years before enrollment (with the exception of early carcinoma that had been treated with curative intent), a history of systemic chemotherapy for mCRC, or who had previously received oxaliplatin or cetuximab were excluded. This biomarker study was conducted in accordance with the Declaration of Helsinki and was approved by the ethical committee of each participating institution. Written informed consent was obtained from all patients before enrollment.
Chemotherapy
In the JACCRO CC-05 trial, patients received modified- on day 1 of each 21-day treatment cycle plus cetuximab. In both trials, treatment was continued until disease progression, unacceptable toxic effects developed, a complete response was achieved, surgical resection became possible, or the patient requested or the physician decided that therapy should be withdrawn.
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Assessment of Efficacy
The primary endpoint of the 2 phase II trials was the objective response rate (ORR) (complete or partial response). Secondary endpoints included progression-free survival (PFS), based on disease progression as detected by external review or death from any cause, overall survival (OS), secondary resection of metastases with curative intent, and safety. Responses were evaluated according to Response Evaluation Criteria in Solid Tumors, version 1.1, by the investigators and were then validated by an external review board.
RNA Isolation and Gene Expression Analysis
Formalin-fixed, paraffin-embedded (FFPE) tumor specimens were cut into sections with a thickness of 3 or 10 mm. In a preparation for macrodissection, one 3-mm slide was stained with hematoxylin and eosin and was then evaluated for tumor content and marked for areas with dominant tumor foci by a pathologist. Macrodissection was performed for 10-mm slides by scraping the marked areas with a blade to ensure that as many tumor cells as possible were dissected. Total RNA was extracted from FFPE tissue of the tumor samples on 10-mm slides, using an miRNeasy FFPE Kit (QIAGEN KK, Tokyo, Japan) according to the manufacturer's protocol.
Immune-related gene expression levels were measured with the use of an HTG EdgeSeq Oncology Biomarker Panel, which is comprised of probes targeting 354 genes implicated in the host immune response to tumors. Next generation sequencing was used to quantitatively analyze targeted genes (https://www.htgmolecular. com/assays/io).
DNA Isolation and BRAF Mutation Analysis
Genomic DNA was extracted from the FFPE tissue derived from the tumor samples with the use of a QIAamp DNA FFPE Tissue Kit (QIAGEN KK) according to the manufacturer's protocol. BRAF V600E mutations were detected by dye terminator sequencing. Exon 15 of the BRAF gene was amplified by polymerase chain reaction, and the polymerase chain reaction products were then visualized using agarose gel electrophoresis with ethidium bromide staining. The products were directly sequenced with the use of an ABI 3130xl Genetic Analyzer (Thermo Fisher Scientific KK, Yokohama, Japan) according to the manufacturer's instructions.
This study was conducted in accordance with the REporting recommendations for tumor MARKer prognostic studies (REMARK). 15 Tissue analyses were performed at HTG Molecular, Inc (Tucson, AZ) after obtaining approval from the Institutional Review Board of each institution that participated in the JACCRO CC-05/06AR trials (UMIN000010635).
Statistical Evaluation
Univariate Cox regression analysis was conducted in cases that passed the internal Quality Control metrics of the HTG EdgeSeq Oncology Biomarker Panel. The association between NLR and PFS and OS in the entire cohort was evaluated using the Spearman rank correlation coefficient. The median of NLR expression was used as the cutoff to stratify patients to NLR-low and NLR-high groups. The association between NLR-low versus NLR-high groups and clinical outcomes was evaluated using the Fisher Exact test for ORR, and the log-rank test for PFS and OS. The multivariable Cox proportional hazards regression model was fitted to reevaluate the association between NLR groups with PFS and OS adjusting for ECOG PS, the number of organs involved, and tumor location. Tumors located from the cecum to the splenic flexure were classified as right-sided, whereas tumors that involved the splenic flexure, descending colon, sigmoid colon, and rectum were classified as leftsided. The 2-sample t test was performed to investigate which of the top 100 genes associated with survival had significantly different expression levels between the NLR-low group and NLR-high group among all measured genes by Cox proportional-hazards models using the likelihood ratio test statistic.
All tests were 2-sided with a significance level of 0.05. False discovery rate (FDR) multiple testing was used to adjust the P values. FDR P-value < .15 was considered statistically significant. SAS 9.4 software (SAS Institute, Cary, NC) was used to perform all analyses.
Results
Seventy-seven eligible patients were enrolled in the present study (see Supplemental Figure 1 in the online version). The baseline characteristics of the patients are summarized in Supplemental Table 1 (in the online version). Forty-four (57%) of the patients were men, the median age of the patients was 63 years, and 82% had left-sided tumors. In the patient cohort, the ORR was 71.8%. The median PFS and OS were 11.2 months (95% confidence interval [CI], 9.2-14.5 months) and 36.2 months (95% CI, 26.7 to not reached), respectively. Consequently, a total of 71 patients who passed the internal Quality Control metrics and had available data on NLR were included in this analysis.
NLR and Patient Characteristics
The median NLR in the 71 patients was 2.68 (range, 0.78-9.95). The patient characteristics were evaluated according to NLR status (ie, low or high according to the cutoff value of 2.68). The distribution of NLR-low or NLR-high did not differ between left-sided tumors and right-sided tumors (P ¼ .31). BRAF mutations were detected more frequently in patients with NLR-high tumors (18.8% vs. 2.9%; P ¼ .048) (see Supplemental Table 2 in the online version).
Association of NLR With Clinical Outcomes
An analysis using the Spearman rank correlation coefficient indicated that the NLR correlated with PFS (r s ¼ À0.24; P ¼ .040) as well as with OS (r s ¼ À0.29; P ¼ .011) in the entire cohort (see Supplemental Figure 2 in the online version). In the study cohort excluding patients who were censored from the analysis of PFS and OS, the NLR was associated with OS (r s ¼ À0.53; P ¼ .0024), but not with PFS (r s ¼ À0.20; P ¼ .14). When the patients were stratified according to the median value of the NLR, patients with NLR-low (n ¼ 36) had significantly longer PFS than those with NLR-high (n ¼ 35) (median, 11.8 months vs. 9.1 months; hazard ratio [HR], 0.57; 95% CI, 0.33-0.97; P ¼ .036). The median OS in the patients with NLR-low was significantly longer than that in the patients with NLR-high (median, 42.8 months vs. 26.7 months; HR, 0.45; 95% CI, 0.22-0.94; P ¼ .029) (Figure 1 ). The ORR was slightly but not significantly higher in the NLR-low group than in the NLR-high group (75.0% vs. 68.6%; P ¼ .60) ( Table 1 ). The NLR-low group had significantly better outcomes than the NLRhigh group in terms of PFS and OS in a multivariable analysis adjusted for ECOG PS, the number of organs involved, and tumor
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Clinical Colorectal Cancer December 2018 -e743 location (HR, 0.55; 95% CI, 0.31-0.95; P ¼ .033 and HR, 0.44; 95% CI, 0.20-0.96; P ¼ .038, respectively). On the other hand, there was no significant association of outcomes with ECOG PS, the number of organs involved, or tumor location in the multivariable analysis (Table 2) .
We performed an exploratory analysis to investigate the association between the NLR and clinical outcomes according to primary tumor sidedness. The frequency of NLR-low was 33% in the rightsided tumor group and 53% in the left-sided tumor group. Patients with NLR-low had slightly but not significantly better clinical outcomes in terms of PFS and OS regardless of tumor sidedness. Both PFS and OS were numerically longer in NLR-low patients than in NLR-high patients, even among patients with right-sided tumors (see Supplemental Table 3 in the online version).
Immune-related Genes Associated With NLR
First, we checked immune-related genes that were associated with survival in 71 patients by Cox proportional hazards models using the likelihood ratio test statistic. Then, 2-sample t tests were performed to investigate which of the top 100 genes had significantly different expression levels between the NLR-low and NLR-high groups (see Supplemental Table 4 in the online version). The 2-sample t test revealed that the expression levels of the LYZ, TYMP, and CD68 genes differently significantly between the 2 groups (t test P-value < .005; FDR P-value < .15) ( Table 3 ). The expression levels of all 3 genes were higher in patients with NLRhigh than in patients with NLR-low.
Discussion
NLR showed a significant relationship with OS in patients with mCRC treated with first-line cetuximab-based chemotherapy. Our data demonstrated that NLR-low was significantly associated with favorable outcomes as compared with NLR-high when the cutoff value was the median. In addition, this is the first report showing that the expression levels of the LYZ, TYMP, and CD68 genes differed significantly between the NLR-low and NLR-high groups. All of the 3 genes had positive correlation with the NLR.
A few studies suggested that the NLR might serve as a predictor of the response to bevacizumab-based chemotherapy in mCRC 16 ;
however, it is not currently used for treatment decision-making. An Australian multicenter study is ongoing to evaluate the relations between the host inflammatory response as measured by the NLR and treatment outcomes in patients with mCRC who received bevacizumab-based first-and second-line treatment (ClinicalTrials. gov: NCT01588990). On the other hand, a recent retrospective study investigating the role of NLR in patients who received first-line cetuximab treatment for mCRC showed that elevated NLR was an independent predictor of shorter PFS and OS in 95 patients extracted from the clinical database of a single institution. 17 Our results were consistent with those of the previous study, but we could demonstrate that the NLR was significantly associated with the clinical outcomes of cetuximab treatment using data from prospective multicenter trials. The NLR may serve as a prognostic marker in patients with CRC treated with chemotherapy regardless of targeted drugs. In several studies, the NLR independently predicted survival in patients with mCRC treated with chemotherapy followed by resection or chemotherapy when a cutoff value of 5 was used to Immune Genes Dominating the NLR in mCRC e744 -Clinical Colorectal Cancer December 2018 designate NLR-high or NLR-low. 8, 18 A few studies showed that a preoperative NLR of greater than 3 correlated with OS and cancerspecific survival in patients with CRC with resectable tumors. 19, 20 In a post hoc analysis of the MRC COIN trial, a high derived NLR was defined using a cutoff value of ! 2.22. 21 On the other hand, Kubo et al have indicated the impact of the preoperative NLR on long-time survival in patients with CRC using the median value as a cutoff. 22 In our study, we used the median value, 2.68, to divide patients into the NLR-high or NLR-low groups. Accordingly, we performed an exploratory analysis of our cohort using a cutoff value of 5.0 because the value has been used in several previous studies.
The patients with high-NLR had a shorter survival time than those with low-NLR (median PFS, 5.8 vs. 11.3 months; median OS, 27.2 vs. 42.8 months); however, the differences were not statistically significant. The cutoff value used to divide patents into the high-NLR or low-NLR groups may differ among patient cohorts and depend on patient characteristics or tumor status.
The antitumor activity of cetuximab may be affected by extracellular immune mechanisms. We have reported that immunerelated genes are associated with clinical outcomes in patients with mCRC treated with cetuximab. 23 Therefore, immune-related genes in the tumor microenvironment may contribute to NLR status, which is associated with survival of cetuximab treatment. We could identify 3 genes, LYZ, TYMP, and CD68, which contributed to the level of the NLR. TYMP and CD68 are both expressed in macrophages, particularly tumor-associated macrophages (TAMs).
In the tumor microenvironment, TYMP stimulates tumor growth by promoting angiogenesis and evasion of apoptosis. 24 Moreover, it has been reported that TYMP was expressed in tumor-infiltrating macrophages, being associated with tumor angiogenesis and poor prognosis in patients with intestinal-type gastric cancer. 25 Gene expression levels of lysozyme and signal transducer and activator of transcription 1 (STAT1) genes are associated with a macrophage signature. 26 Lysozyme expression levels also positively correlate with the numbers of CD68þpSTAT1þ and CD68þCMAFÀ macrophages. A recent study demonstrated that the combined use of a macrophage marker including CD68 with pSTAT1 or CMAF can identify TAMs that play a significant role in tumor development. 27 Accumulation of the TAMs in the tumor is associated with a high NLR. We investigated number of immune-related genes including cytokine genes using a multi-gene panel. A high NLR has been shown to correlate with a distinct cytokine profile, including proinflammatory cytokines and angiogenic cytokines 3 ; however, we found the 3 macrophage-related genes as significant ones for the NLR status, leading that NLR status might depend on macrophagerelated genes rather than cytokine-related genes. To the best of our knowledge, this is the first time to report that genes encoding for activities on TAMs may affect the NLR related with the outcomes of cetuximab combination chemotherapy.
In this study, the number of registered samples was relatively small. It is difficult to exactly assess the association between the NLR and clinical outcomes in patients with mCRC treated with chemotherapy. However, the results of our study were consistent with those of previous studies. It would be of great interest to investigate whether the NLR can serve as a predictor of the response to chemotherapy in patients with mCRC, potentially providing clinicians with a useful hint on how to improve treatment in CRC. In our study, it was not possible to evaluate the NLR as a predictive marker for the response to cetuximab treatment because the patient cohort comprised only patients who received cetuximab combination chemotherapy.
Conclusion
The NLR is significantly associated with survival time in patients with mCRC treated with first-line chemotherapy with cetuximab. Genes encoding for activities on macrophages may affect the NLR. 
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Clinical Practice Points
Few clinical studies have investigated the association between NLR and treatment with cetuximab-based chemotherapy in mCRC. The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-related genes affect the NLR remain unclear.
In 77 patients with KRAS exon2 wild-type mCRC from prospective trials of first-line chemotherapy with cetuximab, the association between the NLR and clinical outcomes was evaluated using the Spearman rank correlation coefficient. Also, expression levels of 354 immune-related genes were measured in tissue samples by the HTG EdgeSeq Oncology Biomarker Panel.
The Spearman rank correlation coefficient showed that the NLR was associated with PFS and OS. When stratified by the median value of the NLR, both PFS and OS were significantly different between the NLR-low and NLR-high groups. The expression levels of the LYZ, TYMP, and CD68 genes differed significantly between the NLR-low and NLR-high groups. Genes encoding for activities on macrophages may affect the NLR.
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